Skip to main content
Fig. 3 | Antimicrobial Resistance & Infection Control

Fig. 3

From: Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii

Fig. 3

Kaplan-Meier survival estimates among CRAB-BSI patients with Cefoperazone/Sulbactam therapy. a Kaplan-Meier survival estimates among CRAB-BSI patients with Cefoperazone/Sulbactam monotherapy and Cefoperazone/Sulbactam based combination therapy. b Kaplan-Meier survival estimates among CRAB-BSI patients (APACHE II score < 20) with Cefoperazone/Sulbactam monotherapy and Cefoperazone/Sulbactam based combination therapy. c Kaplan-Meier survival estimates among CRAB-BSI patients (APACHE II score ≥ 20) with Cefoperazone/Sulbactam monotherapy and Cefoperazone/Sulbactam based combination therapy. Abbreviations: CRAB-BSI, Acinetobacter baumannii bloodstream infection; APACHE II score, acute physiology and chronic health evaluation II

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us